

Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael O. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger

Judith U. Kim Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Rae Lynn P. Guest

Daniel A. Klein Jason D. Eisenberg Michael D. Specht Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Laura A. Vogel Bryan S. Wade Aaron L. Schwartz Shannon A. Carroll*

Wesley W. Jones' Matthew E. Kelley Michelle K. Holoubek Marsha A. Rose*

Registered Patent Agents • Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse

Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills Danielle L. Letting

Of Counsel Kenneth C. Bass III Marvin C. Guthrie

Admitted only in Maryland Admitted only in Virginia Practice Limited to Federal Agencies

January 13, 2006

(202) 772-8858 INTERNET ADDRESS: JHEIDER@SKGF.COM

Art Unit 1635

Attn: Amendment

WRITER'S DIRECT NUMBER:

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/725,015; Filed: December 2, 2003

For: Method for Producing Sterile Polynucleotide Based Medicaments

Inventors:

GEALL et al.

Our Ref:

1530.0610001/EKS/J-H

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Second Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97(b);
- 2. Form PTO/SB/08A (1 page), citing 4 documents (AH3, AI3, AN2 and AO2);
- 3. 1 copy of the 2 cited documents (AN2 and AO2); and
- 4. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox P.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents January 13, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ulie A. Heider

Agent for Applicants Registration No. 54,161

EKS/J-H/eaf Enclosures

483505v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 3181

1635

GEALL et al.

Art Unit:

Examiner:

Schnizer, R. A.

Filed: December 2, 2003

Appl. No.: 10/725,015

Atty. Docket: 1530.0610001/EKS/J-H

Method for Producing Sterile Polynucleotide Based

Medicaments

Second Supplemental Information Disclosure Statement

Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form PTO/SB/08A are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on June 9, 2005 in connection with the above-captioned application. In accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents, documents AH3 to AI3, cited on the attached IDS Form PTO/SB/08A are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Julie A. Heider

Agent for Applicants Registration No. 54,161

Date:

1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

bstitute for form 1449/PTO

Sheet

 (Use as many sheets as necessary)					
1	of	1			

Complete if Known				
Application Number	10/725,015			
Filing Date	December 2, 2003			
First Named Inventor	Andrew GEALL			
Art Unit	1635			
Examiner Name	Schnizer, R. A.			
Attorney Docket Number	1530.0610001/EKS/J-H			

			U.S. PATENT DO	CUMENTS		
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
		Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	
	AH3	5,709,879	01/20/1998	Barchfeld et al.		
	AI3	6,248,363 B1	06/19/2001	Patel et al.		
··· •			-			
<u>.</u>						
		<u> </u>				
	<u> </u>					
	ļ				-	
						
			 			

		Fo	REIGN PATENT DO	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code' Number Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	
					Appear	T ⁶
	AN2	WO 2004/060059	07/22/2004	Vical Incorporated		1
	AO2	WO 2004/060363	07/22/2004	Vical Incorporated		
		·				
		_				$ldsymbol{\sqcup}$
						Ш

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. • Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. • Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.